Deepening our push into capital markets, we are investing in ZILO and Licuido to add regulated transfer agency, issuance and collateral mobility to our capital markets infrastructure built on the XRPL. This comes on the heels of Aviva Investors tokenising its US Dollar Liquidity Fund on the XRPL last week - a clear signal that institutions are ready to move.
Ripple is here to help them.
https://t.co/rn0EJeFybe
🚀 BIG NEWS: Ripple has made a strategic investment in Licuido
Licuido's platform enables issuers to tokenise investment funds within an institutional-grade framework, while providing the secondary market infrastructure to unlock liquidity through collateral trading.
xAI NEWS: Paul Conyngham, a Sydney-based tech entrepreneur and AI consultant, used Grok to finalize a mRNA vaccine construct for his dog Rosie's mast cell cancer.
Paul used three AI models. He combined ChatGPT for initial ideas, AlphaFold for mutation analysis, and Grok took the mutation data and other inputs to create the final sequence for the custom mRNA vaccine targeting those exact mutations.
Paul sequenced Rosie's healthy DNA and the tumor DNA for $3,000 at the University of New South Wales' (UNSW) Ramaciotti Research Centre, in Sydney, Australia.
He partnered with researchers like Prof. Pall Thordarson and Prof. Martin Smith for manufacturing and injection.
They reported a 75% shrinkage in one tumor.